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Abstract
We report from the First International Workshop on positron emission tomography/magnetic
resonance imaging (PET/MRI) that was organized by the University of Tübingen in March 2012.
Approximately 100 imaging experts in MRI, PET and PET/computed tomography (CT), among them
early adopters of pre-clinical and clinical PET/MRI technology, gathered from March 19 to 24, 2012
in Tübingen, Germany. The objective of the workshop was to provide a forum for sharing first-hand
methodological and clinical know-how and to assess the potential of combined PET/MRI in
various applications from pre-clinical research to scientific as well as clinical applications in
humans. The workshop was comprised of pro-active sessions including tutorials, specific
discussion panels and grand rounds. Pre-selected experts moderated the sessions, and feedback
from the subsequent discussions is presented here to a greater readership. Naturally, the
summaries provided herein are subjective descriptions of the hopes and challenges of PET/MR
imaging as seen by the workshop attendees at a very early point in time of adopting PET/MRI
technology and, as such, represent only a snapshot of current approaches.
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MR-based attenuation correction, Workflow, Standardization
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Introduction
Medical imaging using combined multi-modality imag-ing technologies has continuously improved clinical
patient care over the past decade. Recently, a new imaging
modality, combined positron emission tomography/magnetic
resonance imaging (PET/MRI), has been proposed for
application in humans, thus opening the door to true multi-
parametric imaging [1]. After early attempts to solve the
challenges of integrating PET and MRI systems, three
general strategies are now conceived for combining PET
and MRI [2]: separate PET (i.e., PET/computed tomography
(PET/CT) and MRI units, sequential, or co-planar PET/MRI,
and fully integrated PET/MRI systems.
As of today, there are about 40 clinical and ten preclinical
combined PET/MRI systems installed worldwide. Therefore,
exploring any synergistic effects of combining functional
MRI and molecular PET imaging would be of great interest.
In discussions during the meeting, the view emerged that
PET/MRI must offer new areas of application exploiting the
strengths of each technology and, as such, is not seen as
being in conflict with PET/CT. However, while first clinical
studies are currently underway to assess the potential of
combined PET/MRI, several methodological challenges still
need to be addressed before this imaging technology can be
transferred into routine applications.
This workshop was designed specifically to invite pro-
fessionals from complementary disciplines, such as nuclear
medicine and radiology, physics and biology, as well as clinicians
and pharmacists. The overarching goal was to reflect the multi-
disciplinary nature of the combination of imaging hardware by
the multi-disciplinary panel of faculty, experts and attendees.
This article combines summaries of the six breakout
sessions (BS) from the workshop and subsequent panel
discussions, which were either moderated or supported by
the authors of this report. The topics of the breakout sessions
were chosen ahead of the workshop by the organizers of the
meeting in discussions with some workshop attendees and
most of the speakers. In this summary report, we review the
specific roles of both MRI and PET in combined PET/MRI.
Further, we address the need for quantitative imaging,
including mandatory corrections (e.g., attenuation, scatter,
normalization, motion). This leads to a more detailed
perspective on the need for, and application of, quantitative
PET and MRI in the context of PET/MRI and which level of
quantitative accuracy is required for clinical and research
applications. Finally, in light of the use of PET/MRI for
clinical research, the requirements for standardization of
PET/MRI are discussed.
This workshop did not intend to promote one PET/MRI
design over another since sufficient clinical and methodolog-
ical data to validate such a potential preference are missing
today. Furthermore, the issue of cost was not addressed as this
technology is still in an early exploratory phase and future
designs may well be quite different to current versions.
BS 1: the Role of MRI in PET/MRI
The role of MRI in PET/MRI strongly depends on the pre-
selected application of PET/MRI. For example, PET/MRI
can be used in research applications, where access to the
unbiased spectrum of MR-only techniques is desirable,
much like the ability to perform dynamic emission acquisi-
tions, while time constraints as well as diagnostic demands
are less important. Alternatively, PET/MRI can be used
clinically, with the main objective of the examination being
diagnostic, thus, giving priority to other parameters and
rendering a short examination time desirable.
In either scenario, the choice ofMR sequences and the body
region(s) covered by MRI determine the total time of an
examination. MR images are used for anatomical localization,
attenuation correction of PET data and tissue characterization
based on selected functional MRI (fMRI) techniques.
As of today, two approaches towards combined PET/MRI
are available [2]: first, a sequential approach, with the PET and
MR data being acquired in close sequence in time (similar to
PET/CT), and second approach. Here, the PET detector is fully
integrated into the MR system, and PET and MR data can be
acquired simultaneously.
Approaches to both hardware combinations deal with the
challenge of choosing the appropriate MR sequences on top of
the mandatory sequences for deriving the attenuation co-
efficients [3]. A PET/MRI protocol can be performed either
without further ‘morphological’ MRI, thus taking about
25 min, or with a number of additional, diagnostic sequences,
even with the use of intravenous (i.v.) contrast, thus increasing
theMRI acquisition time to 90min or more. In this context, it is
mandatory to tailor individual MRI protocols to the specific
patient and diagnostic question to be answered, thereby
streamlining the data acquisition workflow and shortening the
acquisition time. For true total body and torso imaging,
previous standard multi-station, multi-contrast body part
MRI should be replaced by multi-contrast continuously
moving table data acquisition schemes [4].
Integrated PET/MRI systems also allow for physiological
gating (e.g., by using electrocardiography) as well as MR-
based triggering of the PET data. It was discussed that
motion correction techniques need further improvements to
increase the acceptance level and clinical applicability of
MR-based PET motion correction. Therefore, one require-
ment is to limit the associated increase in examination time
when applying gating methods.
Further considerations relate to the large amount of data
that is generated and that needs to be stored and handled,
which, in turn, requires sophisticated software solutions for
efficient reading dynamic and quantitative assessments.
Finally, reimbursement issues and imaging costs were
discussed as well. Without a doubt, both have a major impact
on the choice of the clinically viable workflows and, therefore,
will in part determine whether PET/MRI is going to become a
high-throughput imaging modality or brand itself into a research
modality.
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BS 2: the Role of PET in PET/MRI
One prerequisite for the combined PET/MRI technique
gaining wider acceptance in the medical imaging com-
munity is the PET sub-system delivering data of similar
quality as that obtained with PET data using PET/CT or
stand-alone PET systems. This holds true for physical
properties like spatial resolution, scatter fraction and,
most importantly, accurate radioactivity quantification
and standardized uptake value (SUV). For example, the
event counting rate and sensitivity performance of an
avalanche photodiode (APD)-based MRI-integrated PET
detector system with an extended 26-cm axial field-of-
view and 60-cm ring diameter, both of which contribute
to improved sensitivity, can be equal to that of a state-
of-the-art photomultiplier tube-based system or even
exceed its performance [5].
With regard to clinical applications, different artifacts
in attenuation correction (AC) maps are produced by
combined PET/MRI compared to PET/CT, most of them
resulting from inaccuracies in the MRI-based AC (e.g.,
metal implants, misclassification of tissue, truncation).
Those occasional artifacts were reported to almost
exclusively occur in the head, torso and extremities and
have to be checked for. Importantly, bony structures are
not considered by the currently applied MR-based AC
method (three- and four-class segmentation), resulting in a
systematic undercorrection of the PET data [3, 6]. This is
particularly important for neuroscience studies considering that
the brain is surrounded by the bony structures of the skull.
However, the determination of the resulting error is still the
subject of ongoing studies.
Overall, the PET image quality and alignment with MR is
subjectively rated high by clinical observers, and the diagnostic
value is comparable with that of standard PET/CT systems. The
known differences in SUVs obtained by combined PET/MRI as
compared to PET/CT require consideration and further research
as they might affect the usefulness of combined PET/MRI in the
evaluation of disease progression and therapy response.
In routine clinical studies, combined PET/MRI has the
opportunity to improve patient comfort and enhance throughput
compared with sequential PET and MRI examinations. Figure 1
provides a “MindMap” for the clinical role of PET/MRI
developed in real time by the participants of this breakout
session. It is evident that the spectrum of expected clinical
applications is wide and covers different fields in oncology,
cardiology and neuroscience imaging.
The experience from PET/CT has been that the speed of the
CT scan, the derivation of CT-based attenuation and scatter
correction algorithms for PET data and the anatomical localiza-
tion afforded by the CT images are all beneficial and provide
essential information from the CT to supplement the PET data.
CT, however, has largely failed to be enhanced from the
inclusion of co-acquired PET data, except in the area of clinical
image interpretation. Due to the different basis for generating
signals in MRI though, it may be that PET and MRI both
contribute useful information to the other modality such as
glucose metabolic rate (FDG-PET) and MR spectroscopy of
metabolic substrates or products in a way that has not occurred
with PET/CT.
Further, for a number of scientific questions, the use of
simultaneous dynamic PET/MRI is potentially preferable over
independent or sequential PET and MRI acquisitions when:
(a) Conventional, non-invasive diagnostic imaging of acute
and changing perfusion conditions of the heart and the
brain (e.g., stress cardiac imaging, acetazolamide-induced
changes in rCBF) by use of contrast-enhanced MRI should
be cross-validated by truly simultaneous perfusion PET.
(b) Kinetic PET data modeling should be performed without
invasive arterial blood sampling by using a PET/MRI-
derived arterial input function.
(c) Functional brain MRI studies, which rely on the blood
oxygen level dependent (BOLD) effect and which, for
instance, display brain response to certain tasks or
pharmacologic agents are paralleled by PET measurements
of neurotransmission to improve the understanding of a
number of different brain disorders.
(d) The nature of the BOLD contrast itself and the neuro-vascular
coupling is further elucidated by simultaneous measurement
of glucose metabolism or cerebral perfusion in PET.
Finally, the exact knowledge of body composition and
organ movement through simultaneous MRI holds the
potential to improve movement correction and the accuracy
of measured SUVs in oncologic PET.
BS 1. The role of MRI in PET/MRI
Key Questions
• How could we structure the examination protocols for PET/MRI for
optimal diagnostic information in a minimum amount of time?
• Are there MR sequences which can be improved or adapted to the needs
of PET/MRI and workflow?
• What are the best software solutions and approaches for convenient and
reliable data storage?
Status Quo
▪ Two general approaches towards combined PET/MRI are available
(simultaneous and sequential) facing similar problems, i.e., choice and
amount of MRI sequences.
▪ There are several possibilities to create PET/MRI protocols depending on
the choice of MR sequences, leading to examination times between 25
and 90 min or longer.
▪ MRI currently is performed in a multi-station, multi-contrast weighting
fashion requiring time-consuming examination planning for whole-
body imaging, thus resulting in non-optimized workflow.
▪ MR-based motion correction is promising in fully integrated systems
with several limitations. Further developments will have an influence
on the acceptance of MR-based motion corrections in clinical routine
examinations.
Conclusions and Open Questions
➢ The amount of MRI performed depends on the underlying pathology,
the clinical work-up as well as patient tolerance.
➢ MRI protocol and imaging workflow optimization is required since
MRI is the limiting factor. This may involve the development and
integration of easy-to-use moving table data acquisition strategies.
➢ Reimbursement will also influence the PET/MRI workflow since it has
a major impact on the patient throughput.
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Many workshop attendees expressed their hopes that
simultaneous PET/MRI, more so than sequential PET/MRI,
would be preferred in selected clinical scenarios when the total
examination time is of essence. In young children, for example,
fully integrated PET/MRI could help reduce the total exami-
nation time and, therefore, the need for, or duration of, sedation
and anesthesia. Also, in an uncooperative patient, simultaneous
examination has distinct advantages.
BS 3: Translational Aspects
The origins of PET/MRI research were in the pre-clinical
field, where first developments and applications date back to
the late 1990s [7–10]. At about the same time, important
progress towards APD-based PET detectors was made by
the Munich group [11].
The pre-clinical imaging arena is an important field to
support subsequent clinical applications. Animal models
can be used to generate specific responder and non-
responder models for diseases and to provide data for
efficient drug development. Combined and fully integrated
PET/MRI systems are potentially helpful in this context.
For example, minute amounts of labeled drugs can be
tracked using high-sensitivity PET, while pharmacodynam-
ic changes or physiological effects (e.g., perfusion)
induced by the drug can be measured at the same time
using arterial spin labelling. It is also feasible to assess
the metabolic profile of the brain during drug application
by MR spectroscopy while observing changes in brain
receptor status using PET at the same time. Control
conditions (e.g., age of animals, nutrition, environmental
factors, etc.) allow an exact characterization of disease
pathways such as in oncology or neurology. In vivo
imaging methods can be easily augmented with ex vivo
methods, such as histology, mass imaging or metabolic
profiling. Here, spectrometry imaging, such as matrix-
assisted laser desorption ionization and secondary ion
mass spectrometry, allows a spatially resolved profiling of
biomolecules by applying, e.g., nuclear magnetic reso-
nance spectroscopy in tissue samples, which is a clear
advantage when studying diseases in animal models. In
addition, animal studies can be used to estimate radiation
exposure (e.g., internal dosimetry) from newly developed
PET tracers for application in humans.
Simultaneity of PET and MRI signal detection is
highly desirable for pre-clinical PET/MRI and advanced
research applications. Compared to humans, small ani-
mals express accelerated physiological parameters such
as heart rate or respiration and even metabolism.
Therefore, an isochronous acquisition of multifunctional
imaging parameters, such as perfusion using MRI and
oxygenation using PET, is even more important since
fluctuations and changes of these parameters occur on a
smaller timescale, thus making a correlation of sequential
measurements challenging.
Another benefit of PET/MRI over PET/CT in small
animals is the reduced radiation exposure of the animals.
In treatment models, where follow-up studies using
multiple time points are desired, repetitive CT measure-
ments can deposit a substantial amount of radiation dose
to the animal, which may even alter experimental
outcomes [12]. Small animal CT doses depend on image
resolution and contrast and can easily add up to 5 Gy
per mouse [13], while the absorbed dose in mice
undergoing a small animal PET study is on the order
of 0.9 Gy [14]. Thus, PET radiation doses are an order
of magnitude lower than those from small animal CT
scans. Another advantage of small animal MR over CT
is also the improved soft tissue characterization, which
can be obtained also, albeit with somewhat limited
success, by using i.v. contrast agents, which, in turn,
may affect the animal model in study. There was a
consensus among the workshop attendees that sequential
PET/MRI appears to be suitable for the pre-clinical field,
however, only if the main focus of the studies is to
compare PET-based function with MR-based anatomy.
Finally, dedicated studies are required to validate the
accuracy and reproducibility of pre-clinical PET/MRI
experiments. In line with clinical PET/MRI, issues like
MR-based AC are important also for small animal PET/
MRI. Multi-center comparability should be encouraged
by dedicated PET/MRI phantoms as part of a standard-
ized quality assurance procedure. The development of
pre-clinical PET/MRI protocols should also center on
hallmarks important for clinical imaging, i.e., high
throughput and robust methods and protocols. However,
dedicated studies of complex functions such as the
underpinnings of the BOLD-fMRI effect might require
BS 2. The role of PET in PET/MRI
Key Questions
• Is the quality of the PET component sufficient for qualitative and
quantitative imaging?
• Is the simultaneous acquisition of (dynamic) PET and MRI necessary in
clinical routine?
Status Quo
▪ The physical parameters of the PET sub-systems of combined PET/MRI
are reported to be satisfactory. Artifacts different from PET/CT occur
occasionally (mostly related to MR-based AC).
▪ SUVs of PET-positive lesions can be reduced compared to PET/CT due
to the inaccurate representation of bone attenuation values in MR-AC.
▪ For a number of important research questions in neuropsychiatry, cardiology
and oncology, simultaneous PET/MRI is potentially preferable.
Conclusions and Open Questions
➢ Despite lower SUVs, the diagnostic quality of PET in PET/MRI is not
impaired compared to PET/CT.
➢ The systematic error of PET data following MR-AC needs to be assessed
further for currently employed three- or four-class segmentation methods.
➢ As far as can be concluded so far, especially imaging of brain disorders, soft
tissue cancers, cancers in the proximity of moving organs, and pediatric
cancers will profit from combined and simultaneous PET/MRI.
➢ Fully integrated PET/MR may further benefit the assessment of cancers
in the proximity of moving organs.
➢ Future research will also focus on potential other clinical and research
applications, for instance, in cardiology.
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more elaborate protocols, which are easier to realize in a
pre-clinical setting.
BS 4: Correction Methods
A key objective of combined PET-based hardware
fusion systems is to maintain the ability to fully
quantify metabolic pathways non-invasively. PET
quantification by means of SUV or more advanced
kinetic modeling is required for clinical imaging of
patients for primary diagnosis and therapy response
assessment as well as for new tracer developments.
Likewise, quantification of dedicated MR signals such
as apparent diffusion coefficient, perfusion, etc., must be
supported in the context of combined multifunctional
PET/MRI (Fig. 2).
Accurate attenuation correction is a prerequisite for
quantitative PET imaging. Furthermore, scatter correction,
a second important correction in PET imaging, may depend
on accurate transmission information. In PET/MRI, the PET
attenuation coefficients are derived from MR images that are
not representative of electron density variations, unlike in
CT and standard PET transmission scanning. Several
approaches deriving attenuation coefficients from MR
images have been proposed and are well summarized in
[15]. Routine applications of MR-based AC, available in
whole-body PET/MRI, are based on the acquisition of
dedicated MR sequences (such as the DIXON sequence
with in-/opposed phase images) and subsequent segmenta-
tion. Alternative algorithms, targeted towards research
applications, apply AC templates in the case of brain PET/
MRI or aim at combining tissue segmentation with atlas
approaches. However, these techniques may lack reproduc-
ibility in situations with non-standard patient anatomy.
Recent theoretical work by Defrise et al. suggests that
time-of-flight information from the PET measurement may
have a role to play in improving the accuracy of MRI-
derived AC maps [16].
Fig. 1. “MindMap” on the clinical role of PET/MRI developed in real time by the participants of the breakout session BS 2
“The role of PET in PET/MRI”.
BS 3. Translational Aspects
Key Questions
• Is pre-clinical PET/MRI beneficial for small animal research?
• What are the advantages of pre-clinical studies compared to clinical studies?
• Which PET/MRI system design is most useful for pre-clinical imaging today?
Status Quo
▪ PET/MRI offers many advantages such as reduced radiation dose,
functional parameters and improved tissue characterization compared
to pre-clinical PET/CT.
▪ First pre-clinical PET/MRI systems are already in use.
▪ Fast physiology in animals as well as higher throughput favour
simultaneous PET/MRI.
Conclusions and Open Questions
➢ Studies are needed to show the quantitative accuracy and
reproducibility of small animal PET/MRI.
➢ Complex research questions can be studied more easily using the
controlled conditions of pre-clinical research.
➢ Sequential approaches are suitable to combine anatomy with function;
however, multifunctional research questions are more likely to be
answered using isochronous PET/MRI.
➢ Translation mandates interdisciplinary training for users.
➢ Funding and cost–benefit models will impact the progress of pre-
clinical PET/MRI.
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In addition to the reproducibility of a selected MR-AC
method, the absolute accuracy is a matter of debate. Interest-
ingly, the acceptance level among the attendees of the breakout
session varied between 0 % and 20 %, depending on the
anticipated PET/MRI application and the personal involvement
of the interviewed expert in research applications. When
discussed further in detail, the acceptance level was considered
to be adjustable to the area of interest, meaning that as long as
the absolute bias is known a priori, it would be acceptable. This
can be seen as somewhat contradictory to the past when some
researchers argued strongly in favour of the non-invasive
imaging and quantification ability of PET. Today, the gold
standard for quantitative accuracy of PET/MRI is PET/CT (i.e.,
CT-based AC), mainly due to the fact that almost no PET-only
systems with standard PET transmission sources are produced
anymore. Furthermore, in clinical PET where the diagnosis is
often based on a qualitative evaluation, the accuracy of
quantification may not be crucial, if residual errors do not
distort image quality. In contrast, brain PET/MRI studies
combining, e.g., PET-based neuroreceptor imaging with fMRI,
or PET/MRI-based therapy response assessment in oncology
disease requires accurate PET quantification, which is, how-
ever, not sufficiently supported by the software in commercial
PET/MRI systems today.
In addition to tissue attenuation, other sources of
attenuation must be considered. These were discussed as
being surface coils, additional positioning devices, MR
contrast agents and the like. Most of these contributions
are understood and corrections (look-up tables) are available
to account for these effects. On the other hand, while
truncation artifacts, arising from the difference in transverse
field-of-view of the PET and MRI, are known from PET/CT
imaging and understood, no fully satisfactory correction
method is yet available in present PET/MRI systems.
Figure 3 summarizes the mandatory corrections in PET/
MRI in the context of the required corrections for either
modality alone. It is clear that, with the integration of PET and
MRI, the number of corrections and their complexity increased.
Most of these corrections (attenuation, scatter and truncation)
are understood today, and first implementations are promising
yet not perfect. Quantitative accuracy is in most clinical cases
as good as in clinical PET/CT, but the reproducibility is lower.
On the upside, the prospects of using the MRI information for
super-corrections of the PET (e.g., motion, partial volume
effect) are big, but practical solutions will require the successful
allocation of a few key applications of PET/MRI in routine
imaging. Otherwise, advanced correction schemes will remain
a niche for clinical researchers.
BS 5: Standardization and Clinical
Trials
The main purpose of therapeutic clinical trials is to
determine the efficacy of a new treatment. In cancer trials,
the ‘ideal’ measure for treatment efficacy is the final
Fig. 2. Quantitative parameters in PET, PET/CT and PET/MR.
BS 4. Correction Methods
Key questions
• Which of the available methods forMR-AC is acceptable for clinical routine?
• What is the level of bias from MR-AC we are prepared to accept in clinical
practice?
Status Quo
▪ Several approaches to MR-AC are available in routine PET/MRI systems,
while being an active field of ongoing research.
▪ There is no accepted correction method for metal implants and bone
implemented in PET/MRI.
▪ First solutions to truncation artifacts are made available, but further work
is needed.
Conclusions and Open Questions
➢ MR-based motion correction, if implemented correctly, is likely to
accelerate the adoption of PET/MRI.
➢ MR-based correction for PET is very promising (e.g., partial volume
correction, model-guided reconstruction).
➢ Corrections for MR non-uniformities are required (depending on choice
of sequence).
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outcome based on overall survival. Yet, in practice,
overall survival is often not to be used because of the
possibly extended life expectancy of patients and hence
prolonged duration of the trial. In these cases, patients
will undergo other treatments after the trial is concluded
and, consequently, overall survival is affected not only
by the drug under evaluation but also by other
treatments. Furthermore, early response monitoring and
response prediction is particularly important as quality of
life and survival have to be considered. In addition, the
high cost of a new treatment ideally requires prediction
of response early after the onset of therapy under
investigation.
Therapeutic clinical trials frequently rely on surrogate
endpoints. A surrogate endpoint, or ‘biomarker’, is a
laboratory or image-based measurement or physical sign
used in therapeutic trials as a substitute for a clinically
meaningful endpoint (e.g., overall survival) that is a
direct measure of how a patient feels, functions or
survives and is expected to predict the effect of the
therapy. There are several biomarkers at hand that may
act as surrogate endpoints. Imaging biomarkers are
physical entities or images of these entities that can be
measured and used to indicate a biological process,
disease process or drug response. CT, MRI, PET and
PET/CT are nowadays used in various ways in clinical
trials.
The use of morphologic CT as biomarker was first
established by the publication of the Response Evalua-
tion Criteria in Solid Tumors (RECIST) [17, 18]. The
RECIST criteria were established by an international
collaboration, including the European Organisation for
Research and Treatment of Cancer (EORTC), National
Cancer Institute of the United States and the National
Cancer Institute of Canada Clinical Trials Group. These
criteria represent a set of rules that define when cancer
patients improve (“respond”), stay the same (“stabilize”)
or worsen (“progression”) during treatments based on
tumour size changes seen on CT. Almost at the same
time in 1999, Young et al. published the EORTC
2-deoxy-2-[18 F]fluoro-D-glucose ([18F]-FDG) PET
response criteria [19]. In 2009, Wahl et al. published a
paper entitled “From RECIST to PERCIST: evolving
considerations for PET response criteria in solid
tumors”, providing recommendations for, amongst
others, 18F-FDG PET image analysis and response
evaluation [20].
Ideally, biomarkers, including those based on imag-
ing, should not only indicate a biological process,
disease process or drug response, but they should also
provide accurate and reproducible quantitative measures
of these processes. Precision is of utmost importance as
unwanted variability in (imaging) results may obscure or
underestimate the efficacy of the new drug. Therefore,
standardization of imaging procedures is essential in
clinical trials, particularly multi-center clinical trials [21,
22]. The level and type of standardization may,
however, depend on the specific utility of the imaging
test during the trial. Imaging can be used to determine
patient eligibility to participate in the trial (based on
staging or disease severity), stratify patients into various
trial arms or measure treatment response during or after
the treatment.
During the breakout session on this topic, there was
general consensus that when imaging is used for
treatment response assessment intra-subject standardiza-
tion of imaging procedures and harmonization of imaging
equipment performance is essential. This is of importance
not only for PET but also for other functional imaging
methods, such as CT or MRI perfusion, MRI diffusion
and MRI spectroscopy. When using imaging to obtain
absolute measures, however, higher standards are re-
quired, such as inter-subject or even cross-center stan-
dardization. However, these standards were considered
difficult to achieve at best.
Several issues that may hamper these harmonization
efforts were raised, such as:
 Ongoing technological advances are more quickly intro-
duced than standards.
 Several organizations have similar yet different standards
and system calibration/validation programs.
 Imaging system vendors have not yet implemented
acquisition, reconstruction and analysis protocols or tools
resulting in harmonized imaging results.
A pragmatic solution for trials could be to define
standards for the execution of the imaging procedure in
combination with a minimal performance standard for the
equipment (verified by quality control experiments) and
with centralized reading and analysis of the CT, MRI,
PET or PET/CT images. Central analysis by an imaging
core laboratory could include post-processing steps to
harmonize quantitative results derived from these images.
Finally, it was acknowledged that despite the present
Fig. 3. Mandatory corrections and quality control measures
in PET only, PET/CT, and PET/MR imaging.
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(large) variability in imaging procedures [23], CT, MRI,
PET and PET/CT have made major contributions in
improving patient diagnostic accuracy together with an
impact on patient management [24]. Despite the fact that
the PET/MRI technology is still evolving, it has a great
potential to provide unique information and quantitative
parameters for therapy response monitoring in clinical
trials.
BS 6: Quantitative PET and MRI
When combined in an integrated system, both PET and
MRI should maintain their ability to quantify metabolic
pathways and physiologic processes in vivo. Therefore,
combined PET/MRI technology requires proof of limited
cross-talk effects of the two imaging sub-systems. In
sequential PET/MRI, the ability of PET to assess and
quantify physiological and pharmacokinetic processes is
not compromised by the MR component. In general, this
also holds true for fully integrated PET/MRI systems [5].
However, due to the limited timing resolution of APDs,
which are a constituent of MRI-compatible, integrated
PET detectors today, time-of-flight emission imaging
cannot be performed with the integrated PET/MR system
available today.
Another factor related to the possibility of the PET sub-system
of combined PET/MRI to deliver quantitative read-outs is the
accuracy of the attenuation correction. Here the current
approaches towards MR-AC employing tissue classification [3,
6]) may result in misclassifications and thus incorrect tracer
uptake quantification. Further, neither of the three- or four-class
MR-AC method does account for the presence of bone. This
seems to result, for instance, for combined brain imaging, in a
cranio-caudal gradient of the reconstructed PET tracer distribu-
tion, which is observed neither in PET nor in PET/CT images.
Therefore, normal databases of stand-alone PET or PET/CT
images should be used with caution when analyzing PET data
from combined PET/MRI examinations. Further work is required
for accurate PET quantification following MR-AC in combined
PET/MRI, for instance, by incorporating bone information as
obtained by ultra-short echo time MRI sequences or by
employing artificial intelligence, like support-vector machine
learning [15]. In addition, truncation artifacts arising from the
limited axial field-of-view of theMR system can lead to incorrect
quantification of whole-body PET tracer biodistribution with
implications, for instance, in whole body PET tracer dosimetry
[25]. Finally, the possibilities for image-derived input functions
(IDIF) were discussed in the context of PET/MRI examinations.
Access to an IDIF would help simplify full kinetic PET tracer
modeling by avoiding invasive arterial blood sampling.
One example of an important research application of
simultaneous PET/MRI is related to the possibility to cross-
evaluate quantitative read-outs obtained by both modalities
in the clinical condition of acute ischemic stroke. Here it is
now possible for the first time to examine the perfusion/
diffusion mismatch penumbra concept against [15O]H2O-
PET, the non-invasive in vivo gold standard for cerebral
blood flow measurement (Fig. 4).
Another possibility to improve PET data quantification in
combined PET/MRI relates to the option to detect organ
movement during image acquisition. With simultaneous
PET/MRI imaging, the correction of irregular movements
of the urinary bladder or the gut during PET data acquisition
using movement parameters derived from the simultaneous-
ly acquired MRI data becomes generally possible. Up to
now, there is very limited evidence in the literature beyond
respiratory movement correction using such methodology or
simulations in animals or using phantoms.
Concerning MRI data, for sequential PET/MRI systems, the
possibility to absolutely quantify the target parameter is not
affected as long as radiofrequencies (RF) or susceptibility
artifacts by the PET component do not disturb the MR signal
detection. This also holds true for the integrated PET/MRI
systems in which the PET detectors are placed between the RF
BS 5. Standardization and Clinical Trials
Key questions
• Is there a need for (imaging) standardization in clinical trial (and in
clinical practice)?
• How to agree on standards in multi-center trials? Who sets the standards?
• Do we need different standards for single versus multi-center trials?
Status Quo
▪ There is a large variability in applied methodology of imaging
examinations.
▪ Standards and QC experiments are set up by scientific societies, clinical
research organizations and collaborative groups, resulting in different
standards.
▪ Present PET/CT and PET/MRI system vendors do not provide
standardized acquisition, reconstruction and analysis protocols
resulting in harmonized image quality.
Conclusions and Open Questions
➢ Standardization of imaging procedures and performances/quantification
is needed.
➢ Intra-subject standardization, i.e., use of the samemachine in the exact same
way per patient, is essential and feasible in response assessment trials.
➢ Inter-institute harmonization is needed occasionally, depending on the
purpose of imaging within trial, but considered as difficult or even not
feasible.
➢ Standardization is challenged by ongoing technological advances.
➢ Central image analysis and processing (for reaching harmonized results)
may be the solution for now.
➢ Imaging reports need to be standardized as well (i.e., use same
annotations and language).
➢ Despite the use of non-standardized imaging procedures, imaging has
made a significant contribution for improving patient diagnosis with a
direct impact on patient management.
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body coil and the gradient system. One drawback related to
integrated PET/MRI systems is a smaller patient aperture
(60 cm) as compared to PET/CT or stand-alone wide-bore
(70 cm) MRI systems.
In summary, the quantitative performance of the PET
component is not impaired by the MR component, and cross-
talk effects are generally small, if at all noticeable in routine
applications. As a current drawback, for the PET component of
combined PET/MRI, the MRI-based AC methods currently
employed lead to biased PET tracer uptake quantification.
Final Remarks
The workshop attendees agreed that technological prog-
ress has led to the introduction of separate, co-planar and
fully integrated PET/MRI design concepts for the
sequential and quasi-simultaneous acquisition of multi-
parametric imaging data in clinical practice and research.
Thus, combined PET/MRI will open without a doubt
new perspectives in non-invasive imaging as part of
clinical patient management and clinical research
(Fig. 5). However, the current search for a single clinical
“killer application” for PET/MRI continues and may
eventually prove elusive. Even without such a specific
“killer application”, the convenience of easier patient
handling, intrinsic image alignment, improved contrast
and general versatility render PET/MRI desirable for
clinical practice as well as research. Without a doubt
PET/MRI already adds enormous value to pre-clinical
studies of rodents.
However, numerous technological and methodological
issues, as well as questions of standardization, have to be
addressed before prospective multi-center studies help
explore the clinical potential of PET/MRI.
Additional conclusions drawn from the discussions
among the workshop attendees were, in short:
➢ PET/MRI instrumentation and design concepts are work-
in-progress (WIP) with evidence of a steadily growing
installed base of PET/MRI systems.
➢ The full scope of quantitative and dynamic imaging
functionalities must be maintained in combined PET/
MRI.
➢MRI-based attenuation correction is a WIP offer-
ing reasonable accuracy but limited reproducibility
today.
➢ MRI-based motion correction is a WIP without a readily
applicable clinical implementation yet.
➢ Requirements on the accuracy of PET/MRI will be
renegotiated for specific applications.
➢ Pre-clinical PET/MRI is far more advanced than clinical
PET/MRI.
➢ There is an immediate need for pro-active sharing of
know-how among imaging producers and image
users.
➢ In view of a potential clinical adoption of PET/MRI, cost-
effectiveness studies need to be supported, considering
the wide range or national reimbursement policies.
Naturally, the selection of the topics for the individual
breakout sessions was limited to the preferences and needs
felt by the organizers of the meeting and the faculty.
BS 6. Quantitative PET and MRI
Key Questions
• Do the two sub-systems compromise each other in obtaining quantitative
readouts?
• For the PET component of combined PET/MRI, is the tracer uptake
quantification correct?
• How does the MR-based AC affect PET tracer uptake quantification?
• Are there ways to improve PET and MR readout quantification in
combined PET/MRI?
Status Quo
▪ In combined PET/MRI, the quantitative performance of the PET
component is not impaired by the MR component and vice versa.
▪ For the PET component of combined PET/MRI, theMR-basedACmethods
currently employed lead to suboptimal PET tracer uptake quantification.
▪ Combined PET/MRImay help derive suitable image-derived input function,
with implications for simplifying PET tracer kinetic modeling.
▪ Combined PET/MRI offers to improve PET quantification by online
motion correction using information obtained by MR techniques to
track patient and organ motion.
Conclusions and Open Questions
➢ Combined PET/MRI is suitable to cross-evaluate quantitative readout of
both components.
➢ More work is required to optimize MR-based PET data AC.
Fig. 4. Simultaneous quantification of cerebral blood flow
([15O]H2O-PET) and gadolinium bolus Tmax (perfusion-weight-
ed MRI) in a patient with acute ischemic stroke. Deficits in the
right medial cerebral artery territory were found in this case in
both modalities. A simultaneous imaging approach allows to
cross-evaluate and calibrate new MR techniques of CBF
determination in acute stroke against the gold standard [15O]
H2O-PET. Data courtesy of the Department of Nuclear
Medicine, University of Leipzig (Germany).
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Likewise, the references provided in this summary report are
limited to publications available at the time of the workshop;
the bibliography was kept to an absolute minimum without
giving credit to the rapidly expanding database of PET/MR-
related publications over the past year.
Following the successful First PET/MRI workshop
2012, we agreed to start an annual follow-up series of
this application-driven educational event (for more
information, see www.pet-mr-tuebingen.de). The authors
are looking forward to hearing how the field of multi-
modality imaging continues to develop at the Second
PET/MRI Workshop, which will take place in Tübingen
on April 8–12, 2013.
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